抗骨质疏松治疗药物研究的新进展

Research progress on drugs in osteoporosis therapy

骨质疏松是一种常见的全身性骨代谢疾病,主要表现为骨密度与骨量的下降,从而导致继发性骨折。目前,随着其发病率不断增高,骨质疏松已经成为一个世界范围的健康问题和当前医学的研究热点。骨吸收抑制剂主要作用于破骨细胞,通过抑制破骨细胞分化成熟,减少骨吸收;骨形成促进剂主要作用于成骨细胞,激活其骨形成功能,并且有重建骨组织的效应;骨矿化物是防治骨质疏松的基础药物,包括钙剂和维生素D;解偶联剂种类较为单一,代表药物为雷尼酸锶。主要对以上四大类抗骨质疏松药物的研究进展进行介绍。

Osteoporosis （OP） is a systemic bone metabolism disease characterized by a systemic impairment of bone mass, strength,and microarchitecture,which will be result in increasing the propensity of fragility fractures . In recent years, OP becomes a worldwide health problem and a hotspot in medical research due to its increasing incidence . Anti-resorptive drugs inhibit osteoclast differentiation and maturation in order to reduce bone resorption, Bone-anabolic drugs promote the bone for-mation function of osteoblast and reconstruct bone tissue , Bone mineralization-acceleration drugs are the basic material for pre-vention and treatment of osteoporosis , including calcium and vitamin D , Strontium ranelate is the representative drug of un - coupling agents . In this paper,the current progress of osteoporosis treatments were reviewed including these proposed drugs .